文献速递基础与转化研究临床试验与 GCP

甲氨蝶呤发挥抗肿瘤免疫活性并提高实体瘤患者免疫治疗临床疗效

Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy in patients with solid tumors.
PubMed 文献 · Sci Transl Med · 2025-06-04

研究鉴定低剂量甲氨蝶呤(MTX)具有抗肿瘤免疫活性:在小鼠中减少肿瘤转移并增强放疗和免疫检查点阻断疗效,机制涉及选择性诱导肿瘤细胞DNA损伤、激活cGAS-STING通路并抑制ENPP1介导的cGAMP水解。一项初步临床试验显示低剂量MTX联合免疫治疗和放疗对不可切除或转移性实体瘤患者有较好疗效和安全性,结局优于历史对照。

要点

  • 低剂量MTX在小鼠中减少肿瘤转移并增强放疗和免疫检查点阻断治疗疗效。
  • MTX选择性诱导肿瘤细胞DNA损伤、激活cGAS-STING通路并抑制ENPP1介导的cGAMP水解。
  • 初步临床试验显示低剂量MTX联合免疫治疗和放疗在不可切除或转移性实体瘤中疗效和安全性较好。

核心结论

  • 低剂量MTX具有此前未被认识到的免疫刺激功能,为MTX与肿瘤免疫治疗和放疗联合应用于临床提供了依据。

研究设计与样本

  • 研究包含小鼠实验和一项初步临床试验,后者评估低剂量MTX联合免疫治疗和放疗用于不可切除或转移性实体瘤患者。

主要发现

  • MTX治疗减少小鼠肿瘤转移并增强放疗和免疫检查点阻断治疗的疗效。
  • MTX选择性诱导癌细胞DNA损伤、cGAS-STING通路激活和cGAMP生成。
  • MTX结合ENPP1底物结合口袋,抑制ENPP1介导的cGAMP水解和腺苷生成,降低细胞外腺苷并增强宿主STING介导的抗肿瘤免疫。
  • 初步临床试验显示低剂量MTX联合免疫治疗和放疗在不可切除或转移性实体瘤患者中疗效和安全性较好,结局优于历史对照。

关键数值与推荐

  • 低剂量MTX联合免疫治疗和放疗在不可切除或转移性实体瘤患者中显示较好疗效和安全性,结局优于历史对照。

临床怎么用

  • 作者认为这些结果为MTX与肿瘤免疫治疗和放疗联合应用于临床提供了依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Low-dose methotrexate (MTX) is the first-line drug for treating rheumatoid arthritis as an immunosuppressor. We have identified that low-dose MTX exhibits antitumor immune activity. MTX treatment reduced tumor metastasis and enhanced the efficacy of radiation therapy and immune checkpoint blockade therapy in mice. Mechanistically, MTX selectively induced DNA damage, cGAS-STING [cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS)-stimulator of interferon genes (STING)] pathway activation, and cGAMP generation in cancer cells. Furthermore, MTX bound to the substrate-binding pocket of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), inhibiting ENPP1-mediated cGAMP hydrolysis and adenosine generation. Consequently, MTX reduced extracellular adenosine and enhanced host STING-mediated antitumor immunity. In addition, a preliminary clinical trial demonstrated promising efficacy and safety of low-dose MTX in combination with immunotherapy and radiotherapy for patients with unresectable or metastatic solid tumors, showing improved outcomes compared with historical controls. These results highlight the previously unrecognized immunostimulatory functions of MTX and provide a rationale for combining MTX with tumor immunotherapy and radiotherapy in clinical settings.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Yang R, Wang B, Su Z, et al. Methotrexate exerts antitumor immune activity and improves the clinical efficacy of immunotherapy in patients with solid tumors. Sci Transl Med. 2025. PMID: 40465690. doi:10.1126/scitranslmed.adn6921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。